Literature DB >> 10526946

Bronchiectasis with myeloperoxidase antineutrophil cytoplasmic antibody and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody.

W Matsuyama1, J Wakimoto, A Watanabe, I Kubota, Y Hirotsu, A Mizoguchi, F Iwami, M Kawabata, M Osame.   

Abstract

A 56-year-old woman was hospitalized for recurrent hemoptysis. She had been suffering from bronchiectasis for 4 years. Pseudomonas aeruginosa was persistently detected in her sputum. Serum was positive for Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody (BPI-ANCA). She underwent lung resection. Histopathologically, the resected lung showed bronchiectasis with pulmonary fibrosis but did not show vasculitis. Her serum became negative for the ANCAs after the operation. To date, she has no recurrence of hemoptysis. We discuss this case of bronchiectasis with MPO-ANCA and BPI-ANCA and suggest a possible role for ANCAs in chronic airway infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526946     DOI: 10.2169/internalmedicine.38.813

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

2.  Development of microscopic polyangiitis in patients with chronic airway disease.

Authors:  K Takahashi; S Hayashi; O Ushiyama; N Sueoka; M Fukuoka; K Nagasawa
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

3.  Novel insights into the aetiology of granulomatosis with polyangiitis-a case-control study using the Clinical Practice Research Datalink.

Authors:  Fiona A Pearce; Peter C Lanyon; Richard A Watts; Matthew J Grainge; Abhishek Abhishek; Richard B Hubbard
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.